Literature DB >> 20007378

Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.

Natalia Jura1, Yibing Shan, Xiaoxian Cao, David E Shaw, John Kuriyan.   

Abstract

The kinase domain of human epidermal growth factor receptor (HER) 3/ErbB3, a member of the EGF receptor (EGFR) family, lacks several residues that are critical for catalysis. Because catalytic activity in EGFR family members is switched on by an allosteric interaction between kinase domains in an asymmetric kinase domain dimer, HER3 might be specialized to serve as an activator of other EGFR family members. We have determined the crystal structure of the HER3 kinase domain and show that it appears to be locked into an inactive conformation that resembles that of EGFR and HER4. Although the crystal structure shows that the HER3 kinase domain binds ATP, we confirm that it is catalytically inactive but can serve as an activator of the EGFR kinase domain. The HER3 kinase domain forms a dimer in the crystal, mediated by hydrophobic contacts between the N-terminal lobes of the kinase domains. This N-lobe dimer closely resembles a dimer formed by inactive HER4 kinase domains in crystal structures determined previously, and molecular dynamics simulations suggest that the HER3 and HER4 N-lobe dimers are stable. The kinase domains of HER3 and HER4 form similar chains in their respective crystal lattices, in which N-lobe dimers are linked together by reciprocal exchange of C-terminal tails. The conservation of this tiling pattern in HER3 and HER4, which is the closest evolutionary homolog of HER3, might represent a general mechanism by which this branch of the HER receptors restricts ligand-independent formation of active heterodimers with other members of the EGFR family.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20007378      PMCID: PMC2791034          DOI: 10.1073/pnas.0912101106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

Review 1.  The conformational plasticity of protein kinases.

Authors:  Morgan Huse; John Kuriyan
Journal:  Cell       Date:  2002-05-03       Impact factor: 41.582

Review 2.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

3.  PHENIX: building new software for automated crystallographic structure determination.

Authors:  Paul D Adams; Ralf W Grosse-Kunstleve; Li Wei Hung; Thomas R Ioerger; Airlie J McCoy; Nigel W Moriarty; Randy J Read; James C Sacchettini; Nicholas K Sauter; Thomas C Terwilliger
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2002-10-21

4.  Improved methods for building protein models in electron density maps and the location of errors in these models.

Authors:  T A Jones; J Y Zou; S W Cowan; M Kjeldgaard
Journal:  Acta Crystallogr A       Date:  1991-03-01       Impact factor: 2.290

Review 5.  Untangling the ErbB signalling network.

Authors:  Y Yarden; M X Sliwkowski
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

6.  A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.

Authors:  Edgar R Wood; Anne T Truesdale; Octerloney B McDonald; Derek Yuan; Anne Hassell; Scott H Dickerson; Byron Ellis; Christopher Pennisi; Earnest Horne; Karen Lackey; Krystal J Alligood; David W Rusnak; Tona M Gilmer; Lisa Shewchuk
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

7.  ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface.

Authors:  Mitchell B Berger; Jeannine M Mendrola; Mark A Lemmon
Journal:  FEBS Lett       Date:  2004-07-02       Impact factor: 4.124

8.  Structure of the extracellular region of HER3 reveals an interdomain tether.

Authors:  Hyun-Soo Cho; Daniel J Leahy
Journal:  Science       Date:  2002-08-01       Impact factor: 47.728

9.  Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment.

Authors:  Natalia Jura; Nicholas F Endres; Kate Engel; Sebastian Deindl; Rahul Das; Meindert H Lamers; David E Wemmer; Xuewu Zhang; John Kuriyan
Journal:  Cell       Date:  2009-06-26       Impact factor: 41.582

10.  c-erbB-4 protein expression in human breast cancer.

Authors:  T Y Kew; J A Bell; S E Pinder; H Denley; R Srinivasan; W J Gullick; R I Nicholson; R W Blamey; I O Ellis
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

View more
  160 in total

Review 1.  The ERBB network: at last, cancer therapy meets systems biology.

Authors:  Yosef Yarden; Gur Pines
Journal:  Nat Rev Cancer       Date:  2012-07-12       Impact factor: 60.716

2.  ERBB3: Multifunctional enabler or primary actor in pancreatic cancer?

Authors:  Ralf Landgraf
Journal:  Cancer Biol Ther       Date:  2010-09-13       Impact factor: 4.742

3.  Yet another "active" pseudokinase, Erb3.

Authors:  Susan S Taylor; Alexandr P Kornev
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

4.  Asp-960/Glu-961 controls the movement of the C-terminal tail of the epidermal growth factor receptor to regulate asymmetric dimer formation.

Authors:  Katherine S Yang; Jennifer L Macdonald-Obermann; David Piwnica-Worms; Linda J Pike
Journal:  J Biol Chem       Date:  2010-05-27       Impact factor: 5.157

5.  HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

Authors:  Marcia R Campbell; Dhara Amin; Mark M Moasser
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

Review 6.  The spatiotemporal organization of ErbB receptors: insights from microscopy.

Authors:  Christopher C Valley; Keith A Lidke; Diane S Lidke
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-02-01       Impact factor: 10.005

7.  erbB3 is an active tyrosine kinase capable of homo- and heterointeractions.

Authors:  Mara P Steinkamp; Shalini T Low-Nam; Shujie Yang; Keith A Lidke; Diane S Lidke; Bridget S Wilson
Journal:  Mol Cell Biol       Date:  2013-12-30       Impact factor: 4.272

Review 8.  Molecular pathways: HER3 targeted therapy.

Authors:  Kinisha Gala; Sarat Chandarlapaty
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

9.  Protein AMPylation by an Evolutionarily Conserved Pseudokinase.

Authors:  Anju Sreelatha; Samantha S Yee; Victor A Lopez; Brenden C Park; Lisa N Kinch; Sylwia Pilch; Kelly A Servage; Junmei Zhang; Jenny Jiou; Monika Karasiewicz-Urbańska; Małgorzata Łobocka; Nick V Grishin; Kim Orth; Roza Kucharczyk; Krzysztof Pawłowski; Diana R Tomchick; Vincent S Tagliabracci
Journal:  Cell       Date:  2018-09-27       Impact factor: 41.582

Review 10.  Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.

Authors:  Wei Wang; Hua-Fu Zhao; Teng-Fei Yao; Hao Gong
Journal:  Invest New Drugs       Date:  2018-10-24       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.